

## PRESS RELEASE

Lund, May 23 2016



# CombiGene: Key personnel acquire warrants, Board member purchases shares

Key personnel in CombiGene AB have acquired the warrants offered by a decision at the Annual Shareholders' Meeting April 4th. In total, 230 000 warrants were acquired, each giving the warrant holder the right to buy a CombiGene share in May 2019 at a price of 11,1 SEK. May 20th, same day as these transactions, 40 000 shares were acquired on the open market by Board member Lars Thunberg.

The two scientific cofounders David Woldbye and Merab Kokaia acquired 80 000 and 60 000 warrants, respectively. CEO Bengt Westrin acquired 60 000, and CSO Casper Götzsche acquired 30 000. These were the maximum amounts offered, and the subsidiary CombiGene Personal AB which administers this warrant series TO 2 now has 123 760 TO 2 warrants left to be offered as incentives to other key personnel in the future.

The transactions were reported to AktieTorget May 23rd.

---

## About CombiGene AB

*By combining modern neuroscience with recent advances in gene delivery, CombiGene has developed a method shown to suppress epileptic seizures in preclinical studies. The current focus is on continuing to develop this method into an effective and safe therapy for epilepsy patients, but the method may also have development potential as a means of treating other neurological disorders. Founded on the basis of scientific discoveries made at Lund University and the University of Copenhagen, CombiGene has offices at Medicon Village in Lund, Sweden. The company is public and listed on the Swedish marketplace AktieTorget. [www.combigene.com](http://www.combigene.com)*

## For further information:

CombiGene AB (publ)  
Bengt Westrin, CEO  
Tel: +46 70 – 265 48 62  
email: [bengt.westrin@combigene.com](mailto:bengt.westrin@combigene.com)

**Please read MORE FROM THE COMPANY, a newsletter from CombiGene which contains general news and information that is judged not to have a significant effect on the share price. Other issues of MORE FROM THE COMPANY and press releases are available at [www.combigene.com](http://www.combigene.com)**

---

[www.combigene.com](http://www.combigene.com)

CombiGene AB (publ) Medicon Village, SE-223 81 Lund, Sweden  
[info@combigene.com](mailto:info@combigene.com)